The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective analysis of the National Cancer Database

Table 3 Univariate and multivariate Cox analysis of Combining Immunotherapy with Chemotherapy and chemoradiation therapy in PDAC patients who received definitive surgery of the pancreatic tumor

Variable		N (%)	Univariable analysis		Multivariable analysis
Variable		N (%)	Hazard Ratio (95% CI)	P	Hazard Ratio (95% CI)	P
Chemo and immunotherapy combination	Chemotherapy Only	21,198 (99.26%)	Reference		Reference
Chemo and immunotherapy combination	Chemo + Immunotherapy	157 (0.74%)	0.818 (0.668–1.002)	< 0.052	NS	0.435
Chemoradiation and immunotherapy combination	Chemoradiation Only	21,424 (97.94%)	Reference		Reference
Chemoradiation and immunotherapy combination	Chemoradiation + Immunotherapy	452 (2.06%)	0.804 (0.718–0.899)	< 0.0001	0.852 (0.757–0.958)	0.008

Two different models were developed for the multivariable analysis of Table 3 because these variables were mutually exclusive

ISSN: 1748-717X